Aberrant Keap1 methylation in breast cancer and association with clinicopathological features

References

• Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47:89 - 116; http://dx.doi.org/10.1146/annurev.pharmtox.46.120604.141046; PMID: 16968214
   PubMed Web of Science ®Google Scholar
• Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006; 38:769 - 89; http://dx.doi.org/10.1080/03602530600971974; PMID: 17145701
   PubMed Web of Science ®Google Scholar
• Shen G, Kong AN. Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm Drug Dispos 2009; 30:345 - 55; http://dx.doi.org/10.1002/bdd.680; PMID: 19725016
   PubMed Web of Science ®Google Scholar
• MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K, et al. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009; 30:1571 - 80; http://dx.doi.org/10.1093/carcin/bgp176; PMID: 19608619
   PubMed Web of Science ®Google Scholar
• Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009; 34:176 - 88; http://dx.doi.org/10.1016/j.tibs.2008.12.008; PMID: 19321346
   PubMed Web of Science ®Google Scholar
• Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006; 21:689 - 700; http://dx.doi.org/10.1016/j.molcel.2006.01.013; PMID: 16507366
   PubMed Web of Science ®Google Scholar
• Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006; 3:e420; http://dx.doi.org/10.1371/journal.pmed.0030420; PMID: 17020408
   PubMed Web of Science ®Google Scholar
• Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008; 68:1303 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-07-5003; PMID: 18316592
   PubMed Web of Science ®Google Scholar
• Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 2009; 36:131 - 40; http://dx.doi.org/10.1016/j.molcel.2009.07.025; PMID: 19818716
   PubMed Web of Science ®Google Scholar
• Tian H, Zhang B, Di J, Jiang G, Chen F, Li H, et al. Keap1: one stone kills three birds Nrf2, IKKβ and Bcl-2/Bcl-xL. Cancer Lett 2012; 325:26 - 34; http://dx.doi.org/10.1016/j.canlet.2012.06.007; PMID: 22743616
   PubMed Web of Science ®Google Scholar
• Niture SK, Jaiswal AK. INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis. Cell Death Differ 2011; 18:439 - 51; http://dx.doi.org/10.1038/cdd.2010.114; PMID: 20865015
   PubMed Web of Science ®Google Scholar
• Niture SK, Jaiswal AK. Inhibitor of Nrf2 (INrf2 or Keap1) protein degrades Bcl-xL via phosphoglycerate mutase 5 and controls cellular apoptosis. J Biol Chem 2011; 286:44542 - 56; http://dx.doi.org/10.1074/jbc.M111.275073; PMID: 22072718
   PubMed Web of Science ®Google Scholar
• Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008; 135:1358 - 68, 1368, e1-4; http://dx.doi.org/10.1053/j.gastro.2008.06.082; PMID: 18692501
   PubMed Web of Science ®Google Scholar
• Yoo NJKH, Kim HR, Kim YR, An CH, Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 2012; 60:943 - 52; http://dx.doi.org/10.1111/j.1365-2559.2012.04178.x; PMID: 22348534
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011; 71:5081 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-10-4668; PMID: 21676886
   PubMed Web of Science ®Google Scholar
• Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, et al, Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519 - 25; http://dx.doi.org/10.1038/nature11404; PMID: 22960745
   PubMed Web of Science ®Google Scholar
• Yoo NJ, Kim HR, Kim YR, An CH, Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 2012; 60:943 - 52; http://dx.doi.org/10.1111/j.1365-2559.2012.04178.x; PMID: 22348534
   PubMed Web of Science ®Google Scholar
• Muscarella LA, Parrella P, D’Alessandro V, la Torre A, Barbano R, Fontana A, et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 2011; 6:710 - 9; http://dx.doi.org/10.4161/epi.6.6.15773; PMID: 21610322
   PubMed Web of Science ®Google Scholar
• Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010; 16:3743 - 53; http://dx.doi.org/10.1158/1078-0432.CCR-09-3352; PMID: 20534738
   PubMed Web of Science ®Google Scholar
• Takahashi T, Sonobe M, Menju T, Nakayama E, Mino N, Iwakiri S, et al. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer. J Surg Oncol 2010; 101:500 - 6; PMID: 20213688
   PubMed Web of Science ®Google Scholar
• Wong TF, Yoshinaga K, Monma Y, Ito K, Niikura H, Nagase S, et al. Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival. Int J Gynecol Cancer 2011; 21:1428 - 35; http://dx.doi.org/10.1097/IGC.0b013e31822d0eb2; PMID: 21897267
   PubMed Web of Science ®Google Scholar
• Nioi P, Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 2007; 362:816 - 21; http://dx.doi.org/10.1016/j.bbrc.2007.08.051; PMID: 17822677
   PubMed Web of Science ®Google Scholar
• Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 2010; 70:5486 - 96; http://dx.doi.org/10.1158/0008-5472.CAN-10-0713; PMID: 20530669
   PubMed Web of Science ®Google Scholar
• Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer 2011; 11:262; http://dx.doi.org/10.1186/1471-2407-11-262; PMID: 21693047
   PubMed Web of Science ®Google Scholar
• Ronkainen H, Vaarala MH, Kauppila S, Soini Y, Paavonen TK, Rask J, et al. Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma. Oncol Rep 2009; 21:1519 - 23; PMID: 19424632
   PubMed Web of Science ®Google Scholar
• Muscarella LA, Barbano R, D’Angelo V, Copetti M, Coco M, Balsamo T, et al. Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient’s outcome. Epigenetics 2011; 6:317 - 25; http://dx.doi.org/10.4161/epi.6.3.14408; PMID: 21173573
   PubMed Web of Science ®Google Scholar
• Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, et al. Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer 2012; 12:66; http://dx.doi.org/10.1186/1471-2407-12-66; PMID: 22325485
   PubMed Web of Science ®Google Scholar
• Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008; 373:151 - 4; http://dx.doi.org/10.1016/j.bbrc.2008.06.004; PMID: 18555005
   PubMed Web of Science ®Google Scholar
• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354:270 - 82; http://dx.doi.org/10.1056/NEJMra050776; PMID: 16421368
   PubMed Web of Science ®Google Scholar
• Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 1997; 94:10937 - 42; http://dx.doi.org/10.1073/pnas.94.20.10937; PMID: 9380738
   PubMed Web of Science ®Google Scholar
• Montano MM, Chaplin LJ, Deng H, Mesia-Vela S, Gaikwad N, Zahid M, et al. Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis. Oncogene 2007; 26:3587 - 90; http://dx.doi.org/10.1038/sj.onc.1210144; PMID: 17160017
   PubMed Web of Science ®Google Scholar
• Sripathy SP, Chaplin LJ, Gaikwad NW, Rogan EG, Montano MM. hPMC2 is required for recruiting an ERbeta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen. Oncogene 2008; 27:6376 - 84; http://dx.doi.org/10.1038/onc.2008.235; PMID: 18663360
   PubMed Web of Science ®Google Scholar
• Yao Y, Brodie AM, Davidson NE, Kensler TW, Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat 2010; 124:585 - 91; http://dx.doi.org/10.1007/s10549-010-1023-8; PMID: 20623181
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379:432 - 44; PMID: 22152853
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784 - 95; http://dx.doi.org/10.1200/JCO.2009.25.6529; PMID: 20404251
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al, American Society of Clinical Oncology, College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118 - 45; http://dx.doi.org/10.1200/JCO.2006.09.2775; PMID: 17159189
   PubMed Web of Science ®Google Scholar
• Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004; 10:5349 - 54; http://dx.doi.org/10.1158/1078-0432.CCR-04-0555; PMID: 15328171
   PubMed Web of Science ®Google Scholar
• Skillings JH, Mack GA. On the use of a Friedman-type statistic in balanced and unbalanced block designs. Technometrics 1981; 23:171
   Web of Science ®Google Scholar
• Ciampi A, Negassa A, Lou Z. Tree-structured prediction for censored survival data and the Cox model. J Clin Epidemiol 1995; 48:675 - 89; http://dx.doi.org/10.1016/0895-4356(94)00164-L; PMID: 7730923
   PubMed Web of Science ®Google Scholar
• De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, et al, QuED Study Group. Clinical and psychological predictors of incidence of self-reported erectile dysfunction in patients with type 2 diabetes. J Urol 2007; 177:252 - 7; http://dx.doi.org/10.1016/j.juro.2006.08.102; PMID: 17162057
   PubMed Web of Science ®Google Scholar